Safety worries spur Pfizer to drop another obesity pill

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it break into the highly lucrative market for obesity drugs.

Verve’s second swing at gene editing for heart disease shows early promise

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety concerns — at least so far.

Mining the hidden gems in unstructured EMR data

Third Harmonic outlines plans for dissolution

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it pursued after halting work on a different immune drug in 2022.

Millions in the U.S. take this drug. Tariffs could complicate their care.